X4 Pharmaceuticals (XFOR) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue rose to $2.9M from $1.8M YoY, driven by U.S. product sales; net loss narrowed to $20.2M from $29.8M.

• 4WARD enrollment is expected to finish by year-end 2026 after FDA feedback supported reducing the trial target from 176 to 126 participants.

Financial highlights

• Q3 product revenue was $2.8M versus $1.6M YoY; 9M product revenue was $7.6M versus $4.3M, reflecting more patients prescribed XOLREMDI.

• 9M total revenue was $14.4M versus $32.5M YoY; prior-year revenue included $27.6M from the Norgine license, while 2026 included a $5.5M license milestone.

• Q3 operating loss was $20.0M versus $27.5M; 9M operating loss was $56.7M versus $63.2M.

• 9M net loss was $56.6M versus $55.3M; lower operating costs were offset by reduced gains from warrant fair-value changes.

Outlook and guidance

• Enrollment in the global Phase 3 4WARD trial is expected to complete by the end of 2026.

• The global Phase 2b 4STEPS trial is designed for ~25 PCN patients; first enrollment is expected in Q1 2027 and top-line data in Q1 2028.

• Current cash, cash equivalents and marketable securities are expected to fund operations and debt obligations for at least 12 months; additional capital may be needed beyond that period.